Literature DB >> 17356938

A neurokinin 1 receptor antagonist decreases adhesion reformation after laparoscopic lysis of adhesions in a rat model of adhesion formation.

S G Prushik1, C B Aarons, R Matteotti, K L Reed, A C Gower, S E Leeman, A F Stucchi, J M Becker.   

Abstract

BACKGROUND: Up to 94% of patients experience fibrous adhesions after abdominal surgery, and a significant number of these patients require a second operation for open or laparoscopic lysis of adhesions (LOA). The authors have previously shown that inhibition of the binding of tachykinin ligands to the neurokinin 1 receptor (NK-1R) using the neurokinin 1 receptor antagonist (NK-1RA) CJ-12,255 decreases primary adhesion formation and upregulates the peritoneal fibrinolytic system in a rat model. Whereas most studies have focused on the prevention of primary adhesions, few have addressed adhesion reformation after LOA. This study aimed to determine the effects of NK-1RA administration on adhesion reformation and peritoneal fibrinolytic activity after laparoscopic LOA.
METHODS: Adhesions were induced in 31 rats using our previously described ischemic button model. The rats underwent laparoscopy 7 days later, during which adhesions were scored and lysed followed by administration of the NK-1RA or saline. Then 7 days after LOA, 23 rats were killed and adhesions were scored. Eight rats also were killed 24 h after the LOA to obtain peritoneal tissue and fluid, which were analyzed for tissue plasminogen activator (tPA) mRNA expression and peritoneal fibrinolytic activity by reverse transcriptase-polymerase chain reaction (RT-PCR) and bioassay, respectively.
RESULTS: At laparoscopy, 79% +/- 3% of the buttons formed adhesions. In the saline-administered control animals, 42% +/- 3.2% of the buttons reformed adhesions after LOA (p < 0.05), whereas in the animals that received the NK-1RA, 18.2% +/- 3.5% of the buttons reformed adhesions (p < 0.05). As compared with control animals, NK-1RA administration increased tPA mRNA levels by 38% and fibrinolytic activity sixfold (p < 0.05; 7.0 +/- 2.1 U/ml vs 1.2 +/- 0.54 U/ml).
CONCLUSIONS: When administered during laparoscopic LOA, an NK-1RA significantly upregulates peritoneal fibrinolytic activity and decreases adhesion reformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356938     DOI: 10.1007/s00464-007-9248-2

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  42 in total

Review 1.  Neuropeptides: mediators of inflammation and tissue repair?

Authors:  M Schäffer; T Beiter; H D Becker; T K Hunt
Journal:  Arch Surg       Date:  1998-10

Review 2.  Adhesions and chronic pain: an overview of pain and a discussion of adhesions and pelvic pain.

Authors:  M R Punch; R S Roth
Journal:  Prog Clin Biol Res       Date:  1993

3.  Laparoscopic management of acute small bowel obstruction.

Authors:  Jennifer J Y Liauw; Wei-Keat Cheah
Journal:  Asian J Surg       Date:  2005-07       Impact factor: 2.767

4.  Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells.

Authors:  Antonina Azzolina; Antonella Bongiovanni; Nadia Lampiasi
Journal:  Biochim Biophys Acta       Date:  2003-12-07

5.  Long-term prognosis after operation for adhesive small bowel obstruction.

Authors:  Bjørg-Tilde Svanes Fevang; Jonas Fevang; Stein Atle Lie; Odd Søreide; Knut Svanes; Asgaut Viste
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

6.  Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists.

Authors:  T P Fan; D E Hu; S Guard; G A Gresham; K J Watling
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

7.  Does means of access affect the incidence of small bowel obstruction and ventral hernia after bowel resection? Laparoscopy versus laparotomy.

Authors:  Hans-Joachim Duepree; Anthony J Senagore; Conor P Delaney; Victor W Fazio
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

8.  Human lymphocytes express substance P and its receptor.

Authors:  J P Lai; S D Douglas; W Z Ho
Journal:  J Neuroimmunol       Date:  1998-06-01       Impact factor: 3.478

9.  Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide.

Authors:  A Metwali; A M Blum; L Ferraris; J S Klein; C Fiocchi; J V Weinstock
Journal:  J Neuroimmunol       Date:  1994-06       Impact factor: 3.478

10.  Results after laparoscopic lysis of adhesions and placement of seprafilm for intractable abdominal pain.

Authors:  L Khaitan; S Scholz; H L Houston; W O Richards
Journal:  Surg Endosc       Date:  2002-10-29       Impact factor: 4.584

View more
  4 in total

Review 1.  Current strategies and future perspectives for intraperitoneal adhesion prevention.

Authors:  Christoph Brochhausen; Volker H Schmitt; Constanze N E Planck; Taufiek K Rajab; David Hollemann; Christine Tapprich; Bernhard Krämer; Christian Wallwiener; Helmut Hierlemann; Rolf Zehbe; Heinrich Planck; C James Kirkpatrick
Journal:  J Gastrointest Surg       Date:  2012-06       Impact factor: 3.452

2.  Combined intraoperative administration of a histone deacetylase inhibitor and a neurokinin-1 receptor antagonist synergistically reduces intra-abdominal adhesion formation in a rat model.

Authors:  Michael R Cassidy; Alan C Sherburne; Stanley J Heydrick; Arthur F Stucchi
Journal:  Surgery       Date:  2015-03       Impact factor: 3.982

3.  Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways.

Authors:  Michael R Cassidy; Alan C Sherburne; Holly K Sheldon; Melanie L Gainsbury; Stanley Heydrick; Arthur F Stucchi
Journal:  Surgery       Date:  2013-11-14       Impact factor: 3.982

4.  Ultrapure alginate gel reduces adhesion reformation after adhesiolysis.

Authors:  Ankit A Chaturvedi; Roger M L M Lomme; Thijs Hendriks; Harry van Goor
Journal:  Int J Colorectal Dis       Date:  2014-09-13       Impact factor: 2.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.